COVID-19: Boehringer Ingelheim Clinical Trials
Boehringer Ingelheim trials are being conducted all over the world and therefore the current COVID-19 pandemic could affect the conduct of our clinical trial programs. We are assessing the ever changing situation carefully each day making sure that we are doing everything we can to limit the impact COVID-19 could have on our clinical trial programs. Our priority is clearly the safety and wellbeing of all participants, regardless of where they are.
We do our utmost to ensure that the supply of the study drug as well as the study related assessments are not interrupted. We organize, for example, direct-to-patient shipment of the respective study medication wherever possible and have arranged for remote assessments whenever feasible. We may also decide to pause patient recruitment for a certain trial or refrain from initiating new clinical trials or sites for a short period of time. We assess the situation continuously and where it is safe for prospective patients and in line with local regulations, we may restart patient recruitment, as we have already done in a some countries. Although delays in our clinical trials are possible, we endeavor to continue our clinical research programs with the wellbeing of our patients as our guiding principle. For more information about Boehringer Ingelheim clinical trials please go to MyStudyWindow.
For us, clinical trials are the translation of our scientific expertise into health solutions for patients. We will be diligently managing them also in these times of crisis, as we believe that clinical research ultimately paves the way for new treatments to solve many health problems that may affect us today, tomorrow and thereafter.
Furthermore, Boehringer Ingelheim is part of the collective effort to fight COVID-19, although we do not develop human vaccines. However, drawing from our different areas of expertise, we engage in a number of activities to find medical solutions to this pandemic, working closely with academic researchers, international institutions and others in the pharma industry.